ENXTBR:ARGXBiotechs
Argenx Leadership Shift And Vyvgart Milestones Reshape Autoimmune Growth Story
argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson.
The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver.
An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon.
argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...